https://www.selleckchem.com/pr....oducts/danirixin.htm
To describe the case histories of two patients who developed acquired haemophilia A following treatment with alemtuzumab for multiple sclerosis. Two patients, a 48-year-old woman and a 31-year-old woman, developed acquired haemophilia A 21 months after their second doses of alemtuzumab. Both presented with spontaneous bruising, and the second case reported menorrhagia. One patient required treatment to control bleeding. Both patients responded to treatment with prednisolone and cyclophosphamide to eliminate the inhibitor. Acquired hae
Like
Comment
Share
